When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis.
Ontology highlight
ABSTRACT: A striking contrast runs through the last 60 years of biopharmaceutical discovery, research, and development. Huge scientific and technological gains should have increased the quality of academic science and raised industrial R&D efficiency. However, academia faces a "reproducibility crisis"; inflation-adjusted industrial R&D costs per novel drug increased nearly 100 fold between 1950 and 2010; and drugs are more likely to fail in clinical development today than in the 1970s. The contrast is explicable only if powerful headwinds reversed the gains and/or if many "gains" have proved illusory. However, discussions of reproducibility and R&D productivity rarely address this point explicitly. The main objectives of the primary research in this paper are: (a) to provide quantitatively and histo
SUBMITTER: Scannell JW
PROVIDER: S-EPMC4749240 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
ACCESS DATA